超声内镜引导与经内镜逆行胰胆管造影引导胆道引流治疗恶性胆道梗阻:随机对照试验的系统评价与Meta分析
本系统评价与Meta分析纳入6项随机对照试验共577例患者,比较超声内镜引导胆道引流(EUS-BD)与经内镜逆行胰胆管造影引导胆道引流(ERCP-BD)作为恶性胆道梗阻初始治疗的效果与安全性。结果显示两者在支架通畅时间、操作时间、生存期、技术成功、临床成功及总体不良事件上无显著差异,但EUS-BD组住院时间更短,再干预、术后胰腺炎及肿瘤内生/过度生长的风险显著更低。
要点
- EUS-BD与ERCP-BD作为恶性胆道梗阻初始治疗,疗效与安全性相似。
- EUS-BD组住院时间显著缩短,再干预、术后胰腺炎及肿瘤内生/过度生长风险显著更低。
- 两组支架通畅时间、操作时间、生存期、技术成功、临床成功及总体不良事件无显著差异。
核心结论
- EUS-BD与ERCP-BD作为恶性胆道梗阻的初始治疗,疗效与安全性相似。
- EUS-BD的再干预风险、术后胰腺炎风险、肿瘤内生/过度生长风险显著更低,住院时间显著缩短。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、Embase和Cochrane数据库中的随机对照试验。
- 纳入6项随机对照试验,共577例患者。
- 采用随机效应模型计算合并估计值,使用I²统计量评估异质性。
主要发现
- 支架通畅时间:均数差8.18天(95%CI -22.55至38.91),两组无显著差异。
- 操作时间:均数差-6.31分钟(95%CI -12.68至0.06),两组无显著差异。
- 生存期:均数差4.59天(95%CI -34.23至43.40),两组无显著差异。
- 技术成功(RR 1.04,95%CI 0.96-1.13)、临床成功(RR 1.02,95%CI 0.96-1.08)、总体不良事件(RR 0.58,95%CI 0.24-1.43)、胆管炎(RR 1.19,95%CI 0.39-3.61)两组相似。
- 住院时间:均数差-1.03天(95%CI -1.53至-0.53),EUS-BD组显著更短;再干预(RR 0.57,95%CI 0.37-0.88)、术后胰腺炎(RR 0.15,95%CI 0.03-0.66)、肿瘤内生/过度生长(RR 0.28,95%CI 0.11-0.70)EUS-BD组风险显著更低。
关键数值与推荐
- EUS-BD组与ERCP-BD组支架通畅时间均数差8.18天(95%CI -22.55至38.91)。
- EUS-BD组与ERCP-BD组操作时间均数差-6.31分钟(95%CI -12.68至0.06)。
- EUS-BD组与ERCP-BD组生存期均数差4.59天(95%CI -34.23至43.40)。
- EUS-BD组与ERCP-BD组住院时间均数差-1.03天(95%CI -1.53至-0.53)。
- EUS-BD组再干预RR 0.57(95%CI 0.37-0.88),术后胰腺炎RR 0.15(95%CI 0.03-0.66),肿瘤内生/过度生长RR 0.28(95%CI 0.11-0.70)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Increasing evidence supports EUS-guided biliary drainage (EUS-BD) as a potential alternative to ERCP-guided biliary drainage (ERCP-BD) in the primary treatment of malignant biliary obstruction (MBO). This systematic review and meta-analysis aimed to compare the efficacy and safety of both techniques as the initial approach for MBO. METHODS: We systematically searched in MEDLINE, Embase, and Cochrane databases for randomized controlled trials comparing both techniques and reporting at least one of the outcomes of interest. The pooled estimates were calculated using the random-effects model, and I2 statistics were used to evaluate heterogeneity. RESULTS: We included 6 randomized controlled trials (577 patients). There were no significant differences between both groups in terms of stent patency (mean difference [MD], 8.18 days; 95% confidence interval [CI], -22.55 to 38.91), procedure time (MD, -6.31 minutes; 95% CI, -12.68 to 0.06), and survival (MD, 4.59 days; 95% CI, -34.23 to 43.40). Technical success (risk ratio [RR], 1.04; 95% CI, 0.96-1.13), clinical success (RR, 1.02; 95% CI, 0.96-1.08), overall adverse events (RR, 0.58; 95% CI, 0.24-1.43), and cholangitis (RR, 1.19; 95% CI, 0.39-3.61) were also similar between groups. However, the hospital stay was significantly shorter (MD, -1.03 days; 95% CI, -1.53 to -0.53), and the risk of reintervention (RR, 0.57; 95% CI, 0.37-0.88), postprocedure pancreatitis (RR, 0.15; 95% CI, 0.03-0.66), and tumor ingrowth/overgrowth (RR, 0.28; 95% CI, 0.11-0.70) were significantly lower with EUS-BD. CONCLUSIONS: EUS-BD and ERCP-BD had similar efficacy and safety as the initial approach for MBO. However, EUS-BD had a significantly lower risk of reintervention, postprocedure pancreatitis, tumor ingrowth/overgrowth, and reduced hospital stay.
引用
- Barbosa EC, Santo PADE, Baraldo S, et al. EUS- versus ERCP-guided biliary drainage for malignant biliary obstruction: a systematic review and meta-analysis of randomized controlled trials. Gastrointest Endosc. 2024. PMID: 38648989. doi:10.1016/j.gie.2024.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。